Remove Biopharma Remove Healthcare Provider Remove Leads
article thumbnail

Access solutions: the missing link that prevents biopharma innovation from reaching patients

pharmaphorum

However, most models are based on an old-fashioned and expensive call centre-based approach that fails to meet the needs of patients and healthcare providers (HCPs) as consumers. This, once again, leads to abandonment caused by patient out-of-pocket costs as a critical driver in non-adherence.

article thumbnail

Global Biopharma Launches in the New World Order

PM360

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Innovations & Challenges in Brain Health

PM360

One in three people is expected to develop a neurological condition in their lifetime, and neurological diseases are the leading cause of disability. healthcare system over $800 billion annually. From your work on the AstraMerck merger to your leadership at Alnylam, you’ve been in the biopharma industry for over 30 years.

article thumbnail

PaceMate Announces Collaboration with AliveCor to Offer Cutting-Edge Remote Monitoring Platform

Legacy MEDSearch

Through this collaboration, healthcare providers are able to access clinically relevant heart rhythm analyses and actionable reports via PaceMateLIVE to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and drive improvements to patient care and clinical outcomes.

article thumbnail

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017).

article thumbnail

Microscopic Markets with Macroscopic ImpactCrafting personalized campaigns for small patient populations.

PM360

This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. With this in mind, our efforts to reach these people should focus on providing answers, information, and hope—with all the necessary caveats. Many people, cumulatively, are affected.

article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most. Customer conversion and product uptake have largely depended upon live interactions between treating physicians and biopharma representatives (e.g., sales, medical science liaisons, etc.).